Pegozafermin
Modify Date: 2025-06-20 14:44:37
Pegozafermin structure
|
Common Name | Pegozafermin | ||
|---|---|---|---|---|
| CAS Number | 2489589-60-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PegozaferminPegozafermin is a fibroblast growth factor FGF21 (HY-P7012) analog, which is an endogenous metabolic hormone and regulates energy expenditure and glucose and lipid metabolism. Pegozafermin decreases the level of triglyceride (TG), can be used for non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG)[1][2]. |
| Name | Pegozafermin |
|---|
| Description | Pegozafermin is a fibroblast growth factor FGF21 (HY-P7012) analog, which is an endogenous metabolic hormone and regulates energy expenditure and glucose and lipid metabolism. Pegozafermin decreases the level of triglyceride (TG), can be used for non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | High levels of triglyceride (TG) can lead to organ failure, increases risk of cardiovascular disease and acute pancreatitis[1]. Pegozafermin can cause consistent, significant decreases in triglycerides (TG), as well as improvements in hepatic fat and glycemic control[2]. |
| References |
| No Any Chemical & Physical Properties |